SIMEPREVIR PLUS PEGINTERFERON/RIBAVIRIN COST-EFFECTIVENESS ANALYSIS FOR THE TREATMENT OF CHRONIC GENOTYPE 1 HEPATITIS C IN COLOMBIA

被引：1
|
作者：
Ariza, J. G. [1 ]
Taborda, A. [2 ]
Naciben, V [3 ]
Heibeck, M. [4 ]
Westerhout, K. Y. [5 ]
机构：
[1] Janssen, Bogota, Colombia
[2] Johnson & Johnson, Sao Paulo, SP, Brazil
[3] Janssen Pharmaceut, Sao Paulo, Brazil
[4] Pharmerit Int, Berlin, Germany
[5] Pharmerit Int, Rotterdam, Netherlands
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.020
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN26
引用
收藏
页码：A872 / A872
页数：1
相关论文
共 50 条
  • [41] Results of treatment with peginterferon plus ribavirin in patients with chronic hepatitis C
    Pizarro, Carolina
    Venegas, Mauricio
    Hola, Karen
    Smok, Gladys
    Brahm, Javier
    REVISTA MEDICA DE CHILE, 2011, 139 (06) : 704 - 709
  • [42] Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal
    Elbasha E.H.
    Chhatwal J.
    Ferrante S.A.
    El Khoury A.C.
    Laires P.A.
    Applied Health Economics and Health Policy, 2013, 11 (1) : 65 - 78
  • [43] Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C
    Siebert, U
    Sroczynski, G
    Rossol, S
    Wasem, J
    Ravens-Sieberer, U
    Kurth, BM
    Manns, MP
    McHutchison, JG
    Wong, JB
    GUT, 2003, 52 (03) : 425 - 432
  • [44] Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C
    Hauser, Goran
    Awad, Tahany
    Brok, Jesper
    Thorlund, Kristian
    Stimac, Davor
    Mabrouk, Mahasen
    Gluud, Christian
    Gluud, Lise Lotte
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (02):
  • [45] Cost effectiveness of interferon or peginterferon with ribavirin for histologically mild chronic hepatitis C
    Grieve, R.
    Roberts, J.
    Wright, M.
    Sweeting, M.
    DeAngelis, D.
    Rosenberg, W.
    Bassendine, M.
    Main, J.
    Thomas, H.
    GUT, 2006, 55 (09) : 1332 - 1338
  • [46] Cost-efficacy analysis of peginterferon-α2b plus ribavirin compared to peginterferon-α2a plus ribavirin for treatment of chronic hepatitis C
    Malone, DC
    Tran, TT
    PHARMACOTHERAPY, 2004, 24 (10): : 1456 - 1457
  • [47] COST-EFFECTIVENESS OF PEGINTERFERON AND RIBAVIRIN FOR ELDERLY PATIENTS WITH CHRONIC HEPATITIS C: RESULTS BASED ON THE NATIONWIDE HEPATITIS REGISTRATION IN JAPAN
    Shimbo, T.
    Nagata-Kobayashi, S.
    Masaki, N.
    VALUE IN HEALTH, 2011, 14 (07) : A395 - A395
  • [48] The cost-effectiveness analysis of combination of peginterferon alfa-2a and ribavirin versus combination of peginterferon alfa-2b and ribavirin in chronic hepatitis C in Poland
    Orlewska, E
    VALUE IN HEALTH, 2004, 7 (03) : 356 - 356
  • [49] Simeprevir for the treatment of chronic hepatitis C genotype 1 infection
    Takehara, Tetsuo
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2014, 12 (08) : 909 - 917
  • [50] Impact of optimized treatment algorithms on the cost-effectiveness of ribavirin and peginterferon alfa-2B for chronic hepatitis C.
    Wong, JB
    McHutchison, JG
    Manns, MP
    Davis, GL
    Albrecht, JK
    HEPATOLOGY, 2002, 36 (04) : 717A - 717A
12345